Drug Profile

PTX COVID19 B

Alternative Names: PTX-COVID19-B

Latest Information Update: 21 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Providence Therapeutics
Developer Everest Medicines; Providence Therapeutics
Class COVID-19 vaccines; RNA vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II/III COVID 2019 infections

Most Recent Events

18 Feb 2024 Everest Medicines plans to terminate its licence for PTX COVID19 B
29 Mar 2023 Providence Therapeutics Holdings completes a Phase-II trial in COVID-2019 infections (Prevention) in Canada and South Africa (IM, Injection) (NCT05175742)
01 Feb 2023 Providence Therapeutics plans a phase III trial for COVID 19 infections (Prevention) (IM) in 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com